Scleroderma
Scleroderma – rapid skin improvement seen after treatment with fresolimumab
A treatment breakthrough for total body scarring of the skin that can occur in people with systemic sclerosis (scleroderma) could be on the cards thanks to the findings of new research published in the Journal of Clinical Investigation.
Experts worked with 15 people with scleroderma who were treated with either one or two doses of fresolimumab, a new, unapproved drug that targets a chemical mediator in the body known as TGF-beta. Continue reading
Unique bacterial fingerprint identified in systemic sclerosis – finding could lead to better treatments
People with systemic sclerosis have a unique bacterial signature in their colon, a discovery that could lead to better diagnosis and treatment, experts highlight at the European League Against Rheumatism Annual Congress. The findings suggest that changes in the gut ecology could contribute to the clinical symptoms of systemic sclerosis and could be used to diagnose the condition and in the development of alternative treatments. Continue reading
The latest issue of Arthritis Digest magazine is available to download now!
Don’t miss the expert round-up of the latest research in the arthritis arena. Click here to subscribe
Single digital copy – £2.49 / $3.99
Hard copy subscription – £15 for 6 issues
Issue highlights: exclusive interview with Olympic gold medallist, Katherine Grainger, on the back problems that nearly ended her career; all you need to know about ankle surgery; scleroderma symptoms and true story; yoga under the spotlight; dairy and arthritis………… and more!
Internet discussion forums good for well-being, study shows
Online discussion forums have positive links to well-being and are associated with increased community engagement offline, says a new study in Computers in Human Behavior. The research suggests that online forums have benefits for individuals and wider society and are of greater importance than previously realised. Continue reading
Glucosamine – key area of research says new review of the evidence
Glucosamine-chondroitin continues to be an important area of research when it comes to osteoarthritis of the knee, hip and hand joints, says a recent review of the literature in Current Opinion in Rheumatology.
Key findings of the evidence published over an 18-month period highlight that there has been a sustained focus on glucosamine-chondroitin as a therapeutic agent in the medical management of osteoarthritis. Continue reading
